<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H7DC6EF6B03EF48E9B61579D2E6827130" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 2428 IH: Access to Breast Cancer Diagnosis Act of 2019</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2019-05-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">116th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2428</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20190501">May 1, 2019</action-date><action-desc><sponsor name-id="D000624">Mrs. Dingell</sponsor> (for herself, <cosponsor name-id="K000210">Mr. King of New York</cosponsor>, <cosponsor name-id="W000797">Ms. Wasserman Schultz</cosponsor>, <cosponsor name-id="F000466">Mr. Fitzpatrick</cosponsor>, <cosponsor name-id="A000376">Mr. Allred</cosponsor>, and <cosponsor name-id="M001159">Mrs. Rodgers of Washington</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements or treatment limitations with respect to diagnostic examinations for breast cancer that are less favorable than such requirements with respect to screening examinations for breast cancer.</official-title></form><legis-body id="H610BBD2D035245E59BFF91B4CD1D4058" style="OLC"> 
<section id="H178986C5826B46B9BDB3A10AC950D05B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Access to Breast Cancer Diagnosis Act of 2019</short-title></quote>.</text></section> <section id="HD5A8143B4D474653BFEC876B7D5501CC"><enum>2.</enum><header>Requiring parity in cost-sharing and treatment limitations with respect to diagnostic and screening examinations for breast cancer</header> <subsection id="H873006A8A68E423CA4560C0216101E60"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 2719A of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-19a">42 U.S.C. 300gg–19a</external-xref>) is amended by adding at the end the following new subsection:</text> 
<quoted-block style="OLC" id="H16AA2C79CCA5431CABA0C68655A74DC2" display-inline="no-display-inline"> 
<subsection id="HDA3EBEE0C79F427A99CBF0167C2773AE"><enum>(e)</enum><header>Diagnostic and screening examinations for breast cancer parity</header> 
<paragraph id="HA9168532306E44458FEDE2701878945C"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of a group health plan, or a health insurance issuer offering group or individual health insurance coverage, that provides benefits with respect to a diagnostic examination for breast cancer furnished to an individual enrolled under such plan or such coverage, such plan or such coverage shall ensure that—</text> <subparagraph id="H89CC440CDEF24E9EB5E0B19CBCEE15BC"><enum>(A)</enum><text>the cost-sharing requirements applicable to such examination for such individual are no less favorable than such requirements applicable to a screening examination for breast cancer for such individual; and</text></subparagraph> 
<subparagraph id="H884427FAC32C42A9AD987889EFA063A9"><enum>(B)</enum><text>the treatment limitations applicable to such diagnostic examination for breast cancer for such individual are no less favorable than such limitations applicable to a screening examinations for breast cancer for such individual.</text></subparagraph></paragraph> <paragraph id="H2A19C4600C4F4390ABA9688F2E9D974E" commented="no"><enum>(2)</enum><header>Restriction on certain changes</header><text>A group health plan or health insurance issuer may not, for the sole purpose of complying with paragraph (1), increase cost-sharing requirements with respect to screening examinations for breast cancer.</text></paragraph> 
<paragraph id="H2D5C483E92FA43ACA5379C2D467C236D"><enum>(3)</enum><header>Construction</header><text>Nothing in this subsection shall be construed—</text> <subparagraph id="H8CC7544C6B8243BD9ABDEF86BF6A931A"><enum>(A)</enum><text>to require the use of diagnostic examinations for breast cancer as a replacement for screening examinations for breast cancer;</text></subparagraph> 
<subparagraph id="H96F4110649274C858D9DF6D52C79181B"><enum>(B)</enum><text>to prohibit a group health plan or health insurance issuers from requiring prior authorization or imposing other appropriate utilization controls in approving coverage for any screening or diagnostic imaging; or</text></subparagraph> <subparagraph id="H633CA78475D24DE09A25FD94C3451AAF"><enum>(C)</enum><text>to supersede a State law that provides greater protections with respect to the coverage of diagnostic examinations for breast cancer than is provided under this subsection.</text></subparagraph></paragraph> 
<paragraph id="HA0DCD6D26B814136B7023777EDFE3FFE"><enum>(4)</enum><header>Definitions</header><text>In this subsection:</text> <subparagraph id="H1B093AF23F414C799EBD36FED6C7F85C"><enum>(A)</enum><header>Cost-sharing requirement</header><text display-inline="yes-display-inline">The term <quote>cost-sharing requirement</quote> includes a deductible, coinsurance, copayment, and any maximum limitation on the application of such a deductible, coinsurance, copayment, or similar out-of-pocket expense.</text></subparagraph> 
<subparagraph id="H3CAAA6C939854C2D8D2BC59003126CAC"><enum>(B)</enum><header>Diagnostic examination for breast cancer</header><text>The term <quote>diagnostic examination for breast cancer</quote> means a medically necessary and appropriate (as determined by the health care professional treating the individual) examination for breast cancer to evaluate an abnormality in the breast that is—</text> <clause id="H403419528E9F4864AA52729EF722F768"><enum>(i)</enum><text>seen or suspected from a screening examination for breast cancer; </text></clause> 
<clause id="H538CC98B69964FAABED114485F092517"><enum>(ii)</enum><text>detected by another means of examination; or</text></clause> <clause id="HE09FD3EFD8CE45DBB3BF1460F1094C4D"><enum>(iii)</enum><text>suspected based on the medical history or family medical history of the individual.</text></clause></subparagraph> 
<subparagraph id="H36D666F629C248E4836044DFBAC11819"><enum>(C)</enum><header>Examination for breast cancer</header><text>The term <quote>examination for breast cancer</quote> includes such an examination using breast ultrasound, breast magnetic resonance imaging, or mammography.</text></subparagraph> <subparagraph id="HCC28BB4FAA1943D88AE7A0359F427C28"><enum>(D)</enum><header>Treatment limitation</header><text display-inline="yes-display-inline">The term <quote>treatment limitation</quote> includes limits on the frequency of treatment, number of visits, days of coverage, or other similar limits on the scope or duration of treatment.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H0DDA3F2BECB046CA84B02297268A2311"><enum>(b)</enum><header>Application to grandfathered health plans</header><text>Section 1251(a)(4)(A) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18011">42 U.S.C. 18011(a)(4)(A)</external-xref>) is amended—</text> <paragraph id="H95619381337746B9A22E06C1213BC1C0"><enum>(1)</enum><text>by striking <quote>title</quote> and inserting <quote>title, or as added after the date of the enactment of this Act)</quote>; and</text></paragraph> 
<paragraph id="H4ED9C3FBF87B4A65ABE378A98361F0CE"><enum>(2)</enum><text>by adding at the end the following new clause:</text> <quoted-block style="OLC" id="H5EA016B1493A4266A71A90CE2681F080" display-inline="no-display-inline"> <clause id="H10782316AF1D4E95B02F684775F34578"><enum>(v)</enum><text display-inline="yes-display-inline">Section 2719A(e) (relating to parity for diagnostic and screening examinations for breast cancer).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> 
<subsection id="HFC6353329A7D45E3A656341EEA43F6A0"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply with respect to plan years beginning on or after January 1, 2020.</text></subsection></section> </legis-body></bill>

